What moved GV.PA stock higher intraday today?

Heavy order flow pushed GV.PA stock up intraday. Volume of **38,489,238** shares versus average **14,217,513** suggests liquidity-driven moves, not a confirmed fundamental catalyst.

What is Meyka AI's view and grade on GV.PA stock?

Meyka AI rates GV.PA **62.64/100**, Grade **B**, Suggestion **HOLD**. The grade weighs sector and benchmark comparisons, financial metrics and forecasts. This is informational only.

What price target or forecast exists for GV.PA stock?

Meyka AI's model projects a 12-month base case of **€0.0050**, implying **+177.78%** from **€0.0018**. Forecasts are model-based projections and not guarantees.

Is GV.PA stock suitable for long-term investors?

GV.PA stock currently has negative earnings and weak cash flow, making it high risk for long-term portfolios. Investors should wait for revenue growth, margin improvement or financing clarity.

EU Stocks

38,489,238 shares trade Genomic Vision (GV.PA EURONEXT) on 02 Mar 2026: liquidity test ahead

ByDanny Kontos March 2, 2026

GV.PA stock is the day’s most active microcap on EURONEXT intraday, trading at €0.0018 after a +5.88% move on 38,489,238 shares. The surge reflects heavy liquidity rather than fresh company releases; Genomic Vision SA (GV.PA) remains a low-price, high-volatility healthcare name with a market cap of €693,191. For traders watching volume and short-term price discovery, today’s action highlights both opportunity and execution risk in a thin equity.